Search Result

Results for "

A375

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Akt (1) Antibiotic (1) Apoptosis (23) Aquaporin (1) Bacterial (2) Bcr-Abl (1) Caspase (1) CDK (3) CRM1 (1) Cytochrome P450 (1) DGK (1) Dihydroorotate Dehydrogenase (2) DNA/RNA Synthesis (6) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (1) Early 2 Factor (E2F) (1) Endogenous Metabolite (4) Epigenetic Reader Domain (1) ERK (9) FAK (2) Ferroptosis (2) FGFR (1) FLT3 (1) Fungal (1) Haspin Kinase (1) HBV (2) HDAC (2) Histone Methyltransferase (3) HSP (1) IAP (2) JAK (2) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (2) MEK (10) Melanocortin Receptor (1) Microtubule/Tubulin (2) Necroptosis (1) NF-κB (1) Nucleoside Antimetabolite/Analog (2) Organoid (1) p38 MAPK (3) p62 (1) Parasite (1) PARP (1) PD-1/PD-L1 (1) PERK (2) PGE synthase (1) PI3K (2) Potassium Channel (1) PROTACs (7) Proteasome (1) Raf (10) Ras (1) Reactive Oxygen Species (2) Sirtuin (2) Src (2) STAT (4) TNF Receptor (2) Toll-like Receptor (TLR) (2) Topoisomerase (2) Tyrosinase (1) VEGFR (1)
By Research Areas:	Cancer (91) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (7) Metabolic Disease (2) Neurological Disease (3)

By Targets:

ADC Cytotoxin (1)

Akt (1)

Antibiotic (1)

Apoptosis (23)

Aquaporin (1)

Bacterial (2)

Bcr-Abl (1)

Caspase (1)

CDK (3)

CRM1 (1)

Cytochrome P450 (1)

DGK (1)

Dihydroorotate Dehydrogenase (2)

DNA/RNA Synthesis (6)

Drug-Linker Conjugates for ADC (1)

E1/E2/E3 Enzyme (1)

Early 2 Factor (E2F) (1)

Endogenous Metabolite (4)

Epigenetic Reader Domain (1)

ERK (9)

FAK (2)

Ferroptosis (2)

FGFR (1)

FLT3 (1)

Fungal (1)

Haspin Kinase (1)

HBV (2)

HDAC (2)

Histone Methyltransferase (3)

HSP (1)

IAP (2)

JAK (2)

Ligands for Target Protein for PROTAC (1)

MDM-2/p53 (2)

MEK (10)

Melanocortin Receptor (1)

Microtubule/Tubulin (2)

Necroptosis (1)

NF-κB (1)

Nucleoside Antimetabolite/Analog (2)

Organoid (1)

p38 MAPK (3)

p62 (1)

Parasite (1)

PARP (1)

PD-1/PD-L1 (1)

PERK (2)

PGE synthase (1)

PI3K (2)

Potassium Channel (1)

PROTACs (7)

Proteasome (1)

Raf (10)

Ras (1)

Reactive Oxygen Species (2)

Sirtuin (2)

Src (2)

STAT (4)

TNF Receptor (2)

Toll-like Receptor (TLR) (2)

Topoisomerase (2)

Tyrosinase (1)

VEGFR (1)

By Research Areas:

Cancer (91)

Cardiovascular Disease (1)

Infection (3)

Inflammation/Immunology (7)

Metabolic Disease (2)

Neurological Disease (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128224

Antiproliferative agent-13	Others	Cancer
Antiproliferative agent-13 (compound 16c) shows an antiproliferative activity against human A375 cells with an IC₅₀ value of 32.7 nM. Antiproliferative agent-13 can be used for the research of cancer .

HY-161882

PROTAC SMARCA2 degrader-8	PROTACs	Cancer
PROTAC SMARCA2 degrader-8 (compound 1) is a potent SMARCA2 degrader with a DC₅₀ of 28nM in A375 cells .

HY-N3838

Epitulipinolide diepoxide	Others	Cancer
Epitulipinolide diepoxide (compound 9) is a natural compound isolated from the herbs of Liriodendron chinense (Hemsl.) Sarg. Epitulipinolide diepoxide displays cytoxicity in A375 cells, with the IC₅₀ of 52.03 μM .

HY-120607

Chevalone C	Parasite	Infection Cancer
Chevalone C, a meroterpenoid fungal metabolite, shows antimalarial activity with IC₅₀ value of 25.00 μg/mL. Chevalone C has anti-proliferative activity on colon HCT116, liver HepG2 and melanoma A375 cancer cell lines .

HY-120454

G-479	MEK Potassium Channel	Cancer
G-479 is the inhibitor for MEK and hERG channel (IC₅₀=14 μM). G-479 inhibits the proliferation of HCT-116 and A375 with IC₅₀ of 0.049 μM and 0.004 μM. G-479 exhibits good metabolic stability in liver microsomes and good pharmacokinetic characteristics in rats .

HY-N10335

Harringtonolide	FAK	Inflammation/Immunology Cancer
Harringtonolide is a potent RACK1 inhibitor (IC₅₀=39.66 μM in A375 cells). Harringtonolide inhibits the epithelial-mesenchymal transition (EMT) process and cell proliferation by affecting the interaction between FAK and RACK1. Harringtonolide has plant growth inhibitory, antiviral, anti-inflammatory, and antiproliferation activities .

HY-158027

B-Raf IN 17	Raf VEGFR FGFR	Cancer
B-Raf IN 17 (Compound 8e) is a potent and orally active type II multi-kinase inhibitor. B-Raf IN 17 exhibits potent cellular-level suppression of BRAF_WT, VEGFR-2, and FGFR-1 in A375 cell line, with IC₅₀ values of 0.02, 0.18 and 1.65 μM, respectively. B-Raf IN 17 can be used for the research of cancer .

HY-153864

PROTAC MEK1 Degrader-1	PROTACs MEK ERK	Cancer
PROTAC MEK1 Degrader-1 is a PROTAC targeting MEK1 with a pIC₅₀ value of 7.0. PROTAC MEK1 Degrader-1 consists of a MEK1 inhibitor and a von Hippel-Lindau ligand. PROTAC MEK1 Degrader-1 can inhibit ERK1/2 phosphorylation. PROTAC MEK1 Degrader-1 shows an antiproliferative activity against A375 cells .

HY-169086

KL-465	PROTACs	Cancer
KL-465 is a PROTAC degrader for MAGE-A3, that degrades MAGE-A3 with a DC₅₀ of 2 μM in HeLa cell. KL-465 inhibits viability of MAGE-A3 positive cancer cell HCT116, A375 and HeLa. (Blue: Ligand for E3 ligase (HY-151227); Black: Linker (HY-W679862); Pink: Ligand for target protein (HY-169087))

HY-153445A

MEK-IN-6 hydrate	MEK	Cancer
MEK-IN-6 hydrate (compound 69) is a MEK inhibitor. MEK-IN-6 hydrate has an IC₅₀ of 2 nM for A375 cells .

HY-153469

Benzyl DC-81	ADC Cytotoxin	Cancer
Benzyl DC-81 (Compound 6a) is an anticancer agent with antiproliferative activity against A375 and MCF-7 cells .

HY-N12834

Ecdysoside B	Others	Inflammation/Immunology Cancer
Ecdysoside B (compound 6b) is a pregnanoside compound isolated from the plant Ecdysanthera rosea. Ecdysoside B and its derivatives and isomers shows anticancer, immunosuppressive and anti-inflammatory activities. Ecdysoside B shows cytotoxicity to a variety of human tumor cell lines, including PANC-1 (human pancreatic cancer cells), A375 (human melanoma cells) and U87 (brain glioma U87 cells). Ecdysoside B can be used for research in the areas of cancer, immunomodulation and anti-inflammato .

HY-144271

RAF-IN-1	Raf	Cancer
RAF-IN-1 is a potent b/cRAF inhibitor with an IC₅₀s of 3.8 nM, 36 nM, 29.4 nM for cRAF, bRAF ^wt, and bRAF ^V600E. RAF-IN-1 shows cell growth inhibition with GI₅₀s of 3.4 and 2.9 nM for H358 and A375 cell line bearing bRAF ^V600E mutation, respectively .

HY-162900

HSP90-IN-32	HSP	Cancer
HSP90-IN-32 is a Hsp90 C-terminal inhibitor that displays anti-proliferative activities against SKMel173, SKMel103, SKMel19 and A375 cells with IC₅₀ values of 1.01 μM, 0.782 μM, 0.607 μM and 1.413 μM , respectively. HSP90-IN-32 is promising for research of anti-cancer agents .

HY-16667

HLM006474 5 Publications Verification	Early 2 Factor (E2F)	Cancer
HLM006474 is a pan E2F inhibitor, which inhibits E2F4 DNA-binding with an IC₅₀ of 29.8 µM in A375 cells.

HY-144269

SHR902275	Raf	Cancer
SHR902275 is a potent, selective, and orally active RAF inhibitor targeting RAS mutant cancers. SHR902275 has IC₅₀s of 1.6 nM, 10 nM, and 5.7 nM for cRAF, bRAF ^wt, and bRAF ^V600E, respectively. SHR902275 shows cell growth inhibition with GI₅₀s of 1.5 and 0.17 nM, 0.4 nM and 0.32 nM for H358, A375, Calu6, and SK-MEL2 cells respectively .

HY-153738

ERK1/2 inhibitor 9	ERK	Cancer
ERK1/2 inhibitor 9 (Probe 1) is a covalent ERK1/2 inhibitor. ERK1/2 inhibitor 9 shows sub-micromolar activity in cells (A375 GI50=0.47 μM). ERK1/2 inhibitor 9 causes the downregulation of phospho-ERK1/2. ERK1/2 inhibitor 9 tagged trans-cyclo-octene (TCO) and Tz-Thalidomide (tetrazine tagged Thalidomide) can form the corresponding ERK-CLIPTAC to elicit degradation of ERK1/2 .

HY-122506

Salviolone	STAT	Cancer
Salviolone is a natural diterpenoid derivative that can against melanoma cells. Salviolone exhibits a pleiotropic effect against melanoma by hampering cell cycle progression, STAT3 signaling, and malignant phenotype of A375 melanoma cells .

HY-153341

CFT1946	PROTACs Raf	Cancer
CFT1946 is an orally active, CRBN-based and mutant-selective bifunctional degradation activating compound (BiDAC ^™) degrader of BRAF ^V600E with a DC₅₀ of 14 nM in A375 cells. CFT1946 is capable of degrading BRAF V600E (Class I), G469A (Class II), G466V (Class III) mutations, and the p61-BRAF ^V600E splice variant. CFT1946 can be used in tumor research .

HY-13323

CX-5461 30+ Cited Publications	DNA/RNA Synthesis	Cancer
CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC₅₀s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively .

HY-169298

Ferroptosis-IN-15	Ferroptosis	Cancer
Ferroptosis-IN-15 (compound 12) is a potent inhibitor of ferroptosis, with the EC₅₀s of 0.76 and 0.67 μM in A375 cells and 786-O cells, respectively.Ferroptosis-IN-15 is a potential iron chelator and radical trapping antioxidant .

HY-13323A

CX-5461 dihydrochloride 30+ Cited Publications	DNA/RNA Synthesis	Cancer
CX-5461 dihydrochloride is a potent and orally bioavailable inhibitor of Pol I-mediated rRNA synthesis, with IC₅₀s of 142 nM in HCT-116, 113 nM in A375, and 54 nM in MIA PaCa-2 cells, and shows little or no effect on Pol II (IC₅₀ ≥25 μM).

HY-153445

MEK-IN-6	ERK MEK	Cancer
MEK-IN-6 (Example 69) is a MEK inhibitor. MEK-IN-6 inhibits ERK1/2 (Thr202/Tyr204) phosphorylation in A375 cells (IC₅₀: 2 nM). MEK-IN-6 can be used for research of cancer .

HY-N0201

Atractylenolide I 2 Publications Verification	TNF Receptor Toll-like Receptor (TLR) JAK STAT	Cancer
Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.

HY-12842

UC-112	IAP Apoptosis	Cancer
UC-112 is a novel potent IAP(Inhibitor of apoptosis) inhibitor; potently inhibit cell growth in two human melanoma (A375 and M14) and two human prostate (PC-3 and DU145) cancer cell lines(IC50=0.7-3.4 uM).

HY-147788

hDHODH-IN-9	Dihydroorotate Dehydrogenase	Cancer
hDHODH-IN-9 (Compound 3k) is a potent inhibitor of hDHODH with an IC₅₀ of 0.34 μM. hDHODH-IN-9 demonstrates high cytotoxic activity against MCF-7 and A375 cells and good selectivity. hDHODH-IN-9 has the potential for the research of cancer diseases .

HY-117872

Sartorypyrone A 20-O-Acetylsartorypyrone D	Fungal	Infection
Sartorypyrone A (20-O-Acetylsartorypyrone D) is a monocyclic terpenoid isolated from the soil fungus Neosartorya fischeri. Sartorypyrone A exhibits in vitro growth inhibitory activity against MCF-7, NCI-H460, and A375-C5 cell lines, and has potential anticancer properties.

HY-15816A

Ulixertinib hydrochloride 25+ Cited Publications BVD-523 hydrochloride; VRT752271 hydrochloride	ERK	Cancer
Ulixertinib hydrochloride (BVD-523 hydrochloride) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC₅₀ of <0.3 nM against ERK2. Ulixertinib hydrochloride inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .

HY-15610

GDC-0623 5+ Cited Publications RG 7421; MEK inhibitor 1	MEK Apoptosis	Cancer
GDC-0623 (RG 7421) is a potent, ATP-uncompetitive inhibitor of MEK1 (K_i=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC₅₀=42 nM) versus A375 (BRAF ^V600E, EC₅₀=7 nM).

HY-147734

Calpain Inhibitor-2	Others	Cancer
Calpain inhibitors are lipophilic and show moderate to good antiproliferative activity in vitro compared with melanoma cell lines (a-375 and b-16f1) and PC-3 prostate cancer cells. In addition, a member of this group (compound 3) expressed 2 μ M concentration inhibited the invasion of DU-145 cells by 80%.

HY-13323R

CX-5461 (Standard)	DNA/RNA Synthesis	Cancer
CX-5461 (Standard) is the analytical standard of CX-5461. This product is intended for research and analytical applications. CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC50s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively .

HY-15816

Ulixertinib 25+ Cited Publications BVD-523; VRT752271	ERK	Cancer
Ulixertinib (BVD-523; VRT752271) is a potent, orally active, highly selective, ATP-competitive and reversible covalent inhibitor of ERK1/2 kinases, with an IC₅₀ of <0.3 nM against ERK2. Ulixertinib (BVD-523; VRT752271) inhibits the phosphorylated ERK2 (pERK) and downstream kinase RSK (pRSK) in an A375 melanoma cell line .

HY-N0201R

Atractylenolide I (Standard)	TNF Receptor Toll-like Receptor (TLR) JAK STAT	Cancer
Atractylenolide I (Standard) is the analytical standard of Atractylenolide I. This product is intended for research and analytical applications. Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.

HY-P1726A

MSG606 TFA	Melanocortin Receptor	Cancer
MSG606 TFA is a potent human MC1 receptor antagonist (IC₅₀=17 nM). MSG606 TFA also partial agonist at human MC3 and MC5 receptors (EC₅₀ values are 59 and 1300 nM, respectively). MSG606 TFA exhibits binding affinity for A375 melanoma cells in vitro. MSG606 TFA reverses the induced hyperalgesia in female mice, with no effect in male mice.

HY-161628

Tapcin	Topoisomerase	Cancer
Tapcin is a dual inhibitor for topoisomerase I and topoisomerase II, with IC₅₀ of 203 and 71 nM. Tapcin inhibits proliferations of cancer cells A-375, HeLa, Huh7.5, U2-OS, A549, Caco-2 and HT29, with IC₅₀s of 441, 1.04, 40.5, 0.002, 0.006, 0.287 and 0.842 nM, respectively. Tapcin exhibits antitumor activity in HT29 xenograft model .

HY-164474

DS03090629	MEK	Cancer
DS03090629 is an orally active MEK inhibitor that inhibits MEK activity in an ATP-competitive manner. DS03090629 exhibits high affinity for both MEK and phosphorylated MEK, with K_d values of 0.11 and 0.15 nM, respectively. It effectively inhibits the proliferation of BRAF-mutant overexpressing melanoma cell lines, with IC₅₀ values of 74.3 and 97.8 nM for BRAF V600E and MEK1 F53L transfected A375 cells, respectively. DS03090629 holds potential value in the field of anti-melanoma therapy .

HY-117707

EBI-907	Raf	Cancer
EBI-907 is an orally active and highly potent B-Raf ^V600E inhibitor. EBI-907 demonstrates excellent A375 and Colo-205 cellular antiproliferative activity with IC₅₀ values of 13 nM and 14 nM, respectively. EBI-907 can also cause tumor regression in a B-Raf ^V600E-dependent Colo-205 tumor xenograft model of mice. EBI-907 is promising for research of melanoma and B-Raf ^V600E associated cancers .

HY-138098

Sartorypyrone B	Others	Cancer
Sartorypyrone B is a 2β-acetoxyl analogue of chevalone C. Sartorypyrone B is yielded from the ethyl acetate extract of the culture of the marine sponge-associated fungus Neosartorya tsunodae (KUFC 9213). Sartorypyrone B exhibits strong growth inhibitory activity, having GI₅₀s of 17.8, 20.5, and 25.0 μM, respectively, for MCF-7, NCI-H460, and A375-C5. Sartorypyrone B has the potential for the research of breast adenocarcinoma, non-small cell lung cancer, and melanoma diseases .

HY-121255

(-)-Cryptopleurine (R)-Cryptopleurine; NSC 19912	Others	Cancer
(–)-Cryptopleurine is an alkaloid that has been found in Lauraceae and has diverse biological activities. It inhibits the growth of human A375 melanoma, A431 epidermoid carcinoma, A549 lung, MES-SA uterine sarcoma, and MCF-7 breast cancer cells (IC₅₀=3 nM for all).2 (–)-Cryptopleurine inhibits hypoxia-induced gene expression in a hypoxia response element (HRE) reporter assay (IC₅₀=8.7 nM).3 (–)-Cryptopleurine (500 μg/mL) prevents lesion formation in tobacco (N. tabacum) plants infected with tobacco mosaic virus (TMV). It also inhibits protein synthesis by yeast and mammalian ribosomes.

HY-117991

DW10075	Others	Cancer
DW10075 is a novel, highly selective VEGFR inhibitor that targets the VEGF/VEGF receptor (VEGFR) pathway, which has been shown to be an effective anti-angiogenic approach for cancer therapy. Studies have found that DW10075 selectively inhibits VEGFR-1, VEGFR-2, and VEGFR-3 among 21 kinases, while having no effect on the other 18 kinases, including FGFR and PDGFR. In human umbilical vein endothelial cells (HUVECs), DW10075 significantly prevented VEGF-induced activation of VEGFR and its downstream signaling, thereby inhibiting VEGF-induced HUVEC proliferation. In addition, DW10075 dose-dependently inhibited VEGF-induced HUVEC migration and tube formation, and suppressed angiogenesis in the rat aortic ring model and the chick embryo chorionic membrane model. DW10075 also exhibited antiproliferative activity against 22 different human cancer cell lines, with IC50 values ranging from 2.2 μmol/L (for U87-MG human glioblastoma cells) to 22.2 μmol/L (for A375 melanoma cells). In the nude mouse U87-MG xenograft tumor model, oral administration of DW10075 significantly inhibited tumor growth and reduced the expression of CD31 and Ki67 in tumor tissues. In summary, DW10075 is a potential anti-tumor angiogenesis agent that deserves further development.

HY-B0078

Dacarbazine 20+ Cited Publications Imidazole Carboxamide	Nucleoside Antimetabolite/Analog Apoptosis	Cancer
Dacarbazine is a nonspecific antineoplastic (antineoplastic) alkylating agent. Dacarbazine inhibits T and B lymphocyte responses with IC₅₀ of 50 and 10 μg/mL, respectively. Dacarbazine can be used in the study of metastatic malignant melanoma .

HY-126288

ASTX029 4 Publications Verification	ERK Apoptosis	Cancer
ASTX029 (Example 1) is a potent dual ERK1/2 inhibitor (IC₅₀: 2.7 nM). ASTX029 has anti-cancer activity .

HY-162389

Anticancer agent 202	Others	Cancer
Anticancer agent 202 (compound 3) is a Anticancer agent .

HY-B0078R

Dacarbazine (Standard) Imidazole Carboxamide (Standard)	Apoptosis Nucleoside Antimetabolite/Analog	Cancer
Dacarbazine (Standard) is the analytical standard of Dacarbazine. This product is intended for research and analytical applications. Dacarbazine is a nonspecific antineoplastic (antineoplastic) alkylating agent. Dacarbazine inhibits T and B lymphocyte responses with IC₅₀ of 50 and 10 μg/mL, respectively. Dacarbazine can be used in the study of metastatic malignant melanoma .

HY-149005

PRMT5-IN-19	Histone Methyltransferase	Cancer
PRMT5-IN-19 (Compound 41) is an selective orally active non-nucleoside PRMT5 inhibitor with IC₅₀ values of 23.9 nM (radioactive biochemical assay) and 47 nM (AlphaLISA assay). PRMT5-IN-19 can occupy the SAM-binding pocket in PRMT5 and block methyltransferase activity, which displays good selectivity over other PRMTs and PKMTs. PRMT5-IN-19 inhibits cell proliferation by inducing cell apoptosis, and can be used for cancer-related research .

HY-147731

HDAC6-IN-9	HDAC	Cancer
HDAC6-IN-9 (compound 12c) is a potent and selective HDAC6 inhibitor with IC₅₀ values of 11.8, 15.2, 4.2, 139.6, 21.3 nM for HDAC1,HDAC3, HDAC6, HDAC8, HDAC10, respectively. HDAC6-IN-9 shows anti-proliferative activities .

HY-148059

Uplarafenib B-Raf IN 10	Raf	Cancer
Uplarafenib (B-Raf IN 10) (Compound C09) is a BRAF inhibitor with an IC₅₀ between 50 and 100 nM. Uplarafenib shows antitumor activity .

HY-155571

MDM2/XIAP-IN-3	MDM-2/p53 IAP	Cancer
MDM2/XIAP-IN-3 (compound 3e) is a dual MDM2/XIAP inhibitor. MDM2/XIAP-IN-3 reduces MDM2 and XIAP protein levels and increases p53 expression, thereby inhibiting cancer cell growth and causing cell death .

HY-163356

Tubulin polymerization-IN-60	Microtubule/Tubulin Apoptosis	Cancer
Tubulin polymerization-IN-60 (BF3) is a tubulin polymerization inhibitor with anticancer activity. Tubulin polymerization-IN-60 (BF3) belongs to the colchicine binding site inhibitors (CBSIs) and disturbs cell cycle progression leading to G2/M arrest and apoptosis .

HY-B1139

Tolperisone hydrochloride 1 Publications Verification	Apoptosis	Neurological Disease
Tolperisone hydrochloride is a centrally acting muscle relaxant studied in neurological disorders causing pathological rhabdomyosclerosis (pyramidal tract injury, multiple sclerosis, myelopathy, encephalomyelitis), spastic paralysis, and other muscle dystonia-related Encephalopathy. Tolperisone hydrochloride also has antiviral activity .

Cat. No.	Product Name	Target	Research Area

HY-P1726A

MSG606 TFA	Melanocortin Receptor	Cancer
MSG606 TFA is a potent human MC1 receptor antagonist (IC₅₀=17 nM). MSG606 TFA also partial agonist at human MC3 and MC5 receptors (EC₅₀ values are 59 and 1300 nM, respectively). MSG606 TFA exhibits binding affinity for A375 melanoma cells in vitro. MSG606 TFA reverses the induced hyperalgesia in female mice, with no effect in male mice.

Cat. No.	Product Name	Target	Research Area

HY-P99115

Envafolimab ASC 22; KN 035	PD-1/PD-L1	Cancer
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25?nM. Envafolimab has the potential for the research of solid tumors .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-122506

Salviolone	Structural Classification Terpenoids Labiatae Samanea saman (Jacq.) Merr. Diterpenoids Plants	STAT
Salviolone is a natural diterpenoid derivative that can against melanoma cells. Salviolone exhibits a pleiotropic effect against melanoma by hampering cell cycle progression, STAT3 signaling, and malignant phenotype of A375 melanoma cells .

HY-N0201

Atractylenolide I 2 Publications Verification	Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Source classification Astragalus caprinus L. Plants Compositae Disease Research Fields Cancer	TNF Receptor Toll-like Receptor (TLR) JAK STAT
Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.

HY-N4187

Licochalcone D 3 Publications Verification	Chalcones Flavonoids Classification of Application Fields Leguminosae Source classification Phenols Polyphenols Metabolic Disease Plants Inflammation/Immunology Disease Research Fields Glycyrrhiza uralensis Fisch.	NF-κB Apoptosis Reactive Oxygen Species
Licochalcone D, a flavonoid compound mainly existing in the root of Glycyrrhiza uralensis, is a potent and orally active inhibitor of NF-kappaB (NF-κB) p65. Licochalcone D possesses antioxidant, anti-inflammatory, anti-cancer properties .

HY-N3838

Epitulipinolide diepoxide	Structural Classification Natural Products Source classification Magnoliaceae Liriodendron tulipifera L. Plants	Others
Epitulipinolide diepoxide (compound 9) is a natural compound isolated from the herbs of Liriodendron chinense (Hemsl.) Sarg. Epitulipinolide diepoxide displays cytoxicity in A375 cells, with the IC₅₀ of 52.03 μM .

HY-120607

Chevalone C	Infection Triterpenes Microorganisms Classification of Application Fields Terpenoids Source classification Disease Research Fields	Parasite
Chevalone C, a meroterpenoid fungal metabolite, shows antimalarial activity with IC₅₀ value of 25.00 μg/mL. Chevalone C has anti-proliferative activity on colon HCT116, liver HepG2 and melanoma A375 cancer cell lines .

HY-N10335

Harringtonolide	Classification of Application Fields Ketones, Aldehydes, Acids Source classification Cephalotaxus harringtonia Plants Cephalotaxaceae Inflammation/Immunology Disease Research Fields Cancer	FAK
Harringtonolide is a potent RACK1 inhibitor (IC₅₀=39.66 μM in A375 cells). Harringtonolide inhibits the epithelial-mesenchymal transition (EMT) process and cell proliferation by affecting the interaction between FAK and RACK1. Harringtonolide has plant growth inhibitory, antiviral, anti-inflammatory, and antiproliferation activities .

HY-N12834

Ecdysoside B	Apocynaceae Structural Classification Polysaccharides Source classification Plants Saccharides Urceola rosea (Hook. & Arn.) D. J. Middleton	Others
Ecdysoside B (compound 6b) is a pregnanoside compound isolated from the plant Ecdysanthera rosea. Ecdysoside B and its derivatives and isomers shows anticancer, immunosuppressive and anti-inflammatory activities. Ecdysoside B shows cytotoxicity to a variety of human tumor cell lines, including PANC-1 (human pancreatic cancer cells), A375 (human melanoma cells) and U87 (brain glioma U87 cells). Ecdysoside B can be used for research in the areas of cancer, immunomodulation and anti-inflammato .

HY-117872

Sartorypyrone A 20-O-Acetylsartorypyrone D	Structural Classification Microorganisms Terpenoids Source classification Diterpenoids	Fungal
Sartorypyrone A (20-O-Acetylsartorypyrone D) is a monocyclic terpenoid isolated from the soil fungus Neosartorya fischeri. Sartorypyrone A exhibits in vitro growth inhibitory activity against MCF-7, NCI-H460, and A375-C5 cell lines, and has potential anticancer properties.

HY-N0201R

Atractylenolide I (Standard)	Structural Classification Terpenoids Sesquiterpenes Source classification Astragalus caprinus L. Plants Compositae	TNF Receptor Toll-like Receptor (TLR) JAK STAT
Atractylenolide I (Standard) is the analytical standard of Atractylenolide I. This product is intended for research and analytical applications. Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.

HY-138098

Sartorypyrone B	Triterpenes Microorganisms Classification of Application Fields Terpenoids Source classification Disease Research Fields Cancer	Others
Sartorypyrone B is a 2β-acetoxyl analogue of chevalone C. Sartorypyrone B is yielded from the ethyl acetate extract of the culture of the marine sponge-associated fungus Neosartorya tsunodae (KUFC 9213). Sartorypyrone B exhibits strong growth inhibitory activity, having GI₅₀s of 17.8, 20.5, and 25.0 μM, respectively, for MCF-7, NCI-H460, and A375-C5. Sartorypyrone B has the potential for the research of breast adenocarcinoma, non-small cell lung cancer, and melanoma diseases .

HY-N0351

p-Coumaric acid 1 Publications Verification trans-4-Hydroxycinnamic acid	Structural Classification Classification of Application Fields Source classification Plants Endogenous metabolite Monophenols Microorganisms other families Simple Phenylpropanols Phenols Phenylpropanoids Disease Research Fields Cancer	Endogenous Metabolite Bacterial Apoptosis
p-Coumaric acid (trans-4-Hydroxycinnamic acid) is an isomer of cinnamic acid with oral activity. p-Coumaric acid inhibits cell proliferation and promotes apoptosis. p-Coumaric acid has antibacterial, anti-inflammatory, antioxidant and anti-tumor activities .

HY-N0351R

p-Coumaric acid (Standard)	Structural Classification Monophenols Microorganisms other families Simple Phenylpropanols Source classification Phenols Phenylpropanoids Plants Endogenous metabolite	Endogenous Metabolite Bacterial Apoptosis
p-Coumaric acid (Standard) is the analytical standard of p-Coumaric acid. This product is intended for research and analytical applications. p-Coumaric acid (trans-4-Hydroxycinnamic acid) is an isomer of cinnamic acid with oral activity. p-Coumaric acid inhibits cell proliferation and promotes apoptosis. p-Coumaric acid has antibacterial, anti-inflammatory, antioxidant and anti-tumor activities .

HY-B0150

Nicotinamide Maximum Cited Publications 48 Publications Verification Niacinamide; Nicotinic acid amide	Alkaloids Structural Classification Human Gut Microbiota Metabolites Microorganisms Neurological Disease Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	Organoid Endogenous Metabolite Sirtuin HBV
Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD₊, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity .

HY-B0150A

Nicotinamide Hydrochloride Niacinamide Hydrochloride; Nicotinic acid amide Hydrochloride	Infection Structural Classification Alkaloids Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields Cancer	Sirtuin Endogenous Metabolite HBV
Nicotinamide Hydrochloride is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide Hydrochloride also inhibits SIRT1. Nicotinamide Hydrochloride increases cellular NAD₊, ATP, ROS levels. Nicotinamide Hydrochloride inhibits tumor growth and improves survival. Nicotinamide Hydrochloride also has anti-HBV activity .

HY-N0202

Atractylenolide II 3 Publications Verification Asterolide	Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Source classification Astragalus caprinus L. Plants Compositae Disease Research Fields Cancer	ERK Apoptosis p38 MAPK Akt Src STAT
Atractylenolide II (Asterolide) is a sesquiterpenoid compound. Atractylenolide II can induce G1 phase cell cycle arrest and apoptosis in B16 melanoma cells. Atractylenolide II is an orally effective anticancer agent that can exert anti-melanoma effects by inhibiting the STAT3 signaling pathway. In addition, Atractylenolide II has been shown to ameliorate myocardial fibrosis, oxidative stress, and neuroprotective activity .

HY-P99115

Envafolimab ASC 22; KN 035	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25?nM. Envafolimab has the potential for the research of solid tumors .

Cat. No.	Product Name	Chemical Structure

HY-126214S

JH-RE-06-d6
JH-RE-06-d6 is deuterium labele JH-RE-06. JH-RE-06, a potent REV1-REV7 interface inhibitor (IC₅₀=0.78 μM; K_i=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks